US › Healthcare

Transcode Therapeutics Inc (RNAZ)

US · Healthcare · Biotechnology

$4.45+5.45%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-17.8M
Profit YoY
-47.2%
EPS
$-21.28

Key statistics

Market cap
$4.8M
Forward P/E
0.0
P/B
3.86
Book value
$1.36
EPS (TTM)
$-3.71
52-week high
$20.99
52-week low
$3.82
50-day MA
$6.30
200-day MA
$8.50
Beta
1.24

Analyst view

Analysts rate Transcode Therapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $10.00.

Shareholding

Insiders
28.46%
Institutions
6.85%

Largest institutional holders

FundStake
Geode Capital Management, LLC1.34%
UBS Group AG0.87%
Vanguard Capital Management, LLC0.69%
Vanguard Fiduciary Trust Co0.31%
Tower Research Capital LLC0.02%
Wells Fargo & Co0.01%
SBI Securities Co Ltd0.00%
Royal Bank of Canada0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Transcode Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.